Exosome Therapy in Las Vegas: Evidence & FDA Status
Exosomes are cell-released vesicles being studied for possible medical applications. FDA’s safety alert states that there are no FDA-approved exosome products. This page explains the evidence and regulatory questions; it does not offer exosome infusions.
LiveNow Longevity ·
What are exosomes?
Exosomes are small vesicles released by cells. They are not living stem cells. Their contents and composition depend on their source and production process, so products described as exosomes should not be treated as interchangeable.
Research into cell signaling does not establish that a commercial infusion repairs tissue, reverses aging or treats a disease. Evidence must relate to the exact product, route, patient group and proposed use.
FDA status and investigational use
FDA states that exosomes intended to treat human diseases or conditions are generally regulated as drugs and biological products subject to premarket review and approval. An unapproved exosome product is not made lawful simply by describing it as wellness care or adding a disclosure.
For a proposed clinical trial, ask the investigator for the FDA-issued Investigational New Drug application information and study consent materials. A trial registry entry or an establishment registration is not proof of approval or permission to market a product. We do not claim to recruit for, sponsor or provide access to an exosome trial.
Safety, route and sourcing
FDA’s exosome alert followed reports of serious adverse events in patients who received unapproved products. A physician, IV route, supplier certificate or handling protocol cannot establish safety or effectiveness where product-specific evidence is missing.
An IV infusion and a local injection are different exposures. A result from a different route or laboratory experiment cannot be carried over to a clinic’s product. Discuss known risks, unresolved uncertainties and established alternatives with a qualified treating clinician.
Exosomes versus stem cells
Stem cells are living cells; exosomes are vesicles. Some specific cellular therapies have FDA approval for defined diseases. For example, Ryoncil’s approval concerns pediatric steroid-refractory acute graft-versus-host disease. That approval does not extend to exosomes or to general anti-aging use.
There is no exosome protocol price or treatment-booking offer here. A general medical assessment may help clarify a health concern or referral, but it is not a pathway to purchasing an unapproved infusion.
Common Questions
Is exosome therapy available through this page?
No. This is an educational guide, not an exosome treatment offer. It does not arrange infusions, take treatment deposits or confirm access to an investigational product.
Is exosome therapy FDA-approved?
FDA’s exosome safety alert states that there are no approved exosome products. Check the current FDA source for changes; approval of a different cellular product does not change an exosome product’s status.
Can Nevada rules replace federal requirements?
No. A state-law provision or physician license does not override applicable federal requirements for a drug or biological product. No blanket statement of exosome legality is made here.
Does physician supervision or informed consent establish legal access?
No. Consent, physician supervision, a supplier certificate or state permission does not establish that a particular product may be marketed under federal law. The exact product, intended use and applicable regulatory pathway matter.
What should I ask before paying for a proposed treatment?
Ask for the exact product and manufacturer, the proposed route and use, its FDA approval or applicable investigational authorization, the human evidence, material risks, alternatives and a written itemized cost estimate. Trial registration alone is not FDA approval.
General educational information. An individual medical assessment and the exact product’s regulatory status are separate from this guide.